# FDA 483 - PharmaEssentia Corporation, Taichung Plant - September 21, 2023

Source: https://www.globalkeysolutions.net/records/483/pharmaessentia-corporation-taichung-plant/a3ba557a-1490-40a0-a21c-076154f9573e

> FDA 483 for PharmaEssentia Corporation, Taichung Plant on September 21, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: PharmaEssentia Corporation, Taichung Plant
- Inspection Date: 2023-09-21
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Documents

- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/pharmaessentia-corporation-taichung-plant/194f4763-a1eb-4f18-bf2c-64725a35b396)
- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/pharmaessentia-corporation-taichung-plant/9dc88250-9156-45aa-a21a-70c437863018)

## Related Officers

- [Hamet Touré, PharmD MPH, Regulatory Officer](https://www.globalkeysolutions.net/people/hamet-toure-pharmd-mph-regulatory-officer/90e0a7c5-7fff-4dfe-a893-7d7cad038a15)
- [Madushini Dharmasena, Ph.D., Senior Pharmaceutical Quality Assessor](https://www.globalkeysolutions.net/people/madushini-dharmasena-phd-senior-pharmaceutical-quality-assessor/c2889164-8138-4129-a531-fdabde8d1b4b)

Company: https://www.globalkeysolutions.net/companies/pharmaessentia-corporation-taichung-plant/97fafa0d-9006-45e0-a880-334c4e58248a

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd